Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol/AstraZeneca Initiate Phase III Studies Of SGLT-2 Inhibitor Dapagliflozin

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug is on track to become first-in-class treatment for type 2 diabetes.

You may also be interested in...

Novartis To Resubmit Galvus In Mid-2009

Safety study responding to FDA’s “approvable” letter for the type 2 diabetes therapy will take months, not weeks; firm also faces delay for oncologic Tasigna.

Bristol/AstraZeneca Demonstrate Safety In Dapagliflozin Study For Type 2 Diabetes

Companies report Phase IIa data evaluating the sodium-glucose transporter 2 inhibitor at American Diabetes Association meeting.

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts